ICER developed a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies.

Interventions of Interest:

  • tisagenlecleucel (KymriahTM , Novartis)
  • axicabtagene ciloleucel (YescartaTM, Kite Pharma)

Both agents were approved in 2017. Tisagenlecleucel is approved for treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients. Axicabtagene ciloleucel is approved for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma in adult patients.

Date of Review: March 2018

For questions or additional information, please contact info@icer.org.

View the Key Stakeholders List.


Final Documents

Below you will find the final documents from the assessment review process: